Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.
Axicabtagene ciloleucel (axi-cel; Yescarta) was approved by the FDA for the treatment of adult patients with large B-cell lymphoma (LBCL) whose disease was refractory to or which relapsed within 12 month after first-line chemoimmunotherapy, according to a press release from the FDA.1
Results of the phase 3 ZUMA-7 trial (NCT03391466), which examined axi-cel vs standard-of-care (SOC) in patients with relapsed/refractory LBCL, supported the approval. At the 2021 American Society of Hematology Annual Meeting, investigators reported a statistically significant event-free survival (EFS) improvement in those treatment in the active therapy arm.2
At a median follow-up of 24.9 months, findings showed that the median EFS for patients treated with axi-cel and SOC were 8.3 months (95% CI, 4.5-15.8) and 2.0 months (95% CI, 1.6-2.8), respectively (HR, 0.398; 95% CI, 0.308-0.514; P <.0001). The corresponding 2-year EFS rates were 40.5% (95% CI, 33.2%-47.7%) and 16.3% (95% CI, 11.1%-22.2%) in each respective group.
Updated findings showed that independent review committee–assessed best objective response rate was significantly improved with axi-cel at 83% (95% CI; 77%-88%) vs 50% (95% CI; 43%-58%) with SOC.
Standard of care in the second-line curative setting is salvage chemotherapy followed by consolidation high-dose therapy (HDT)–autologous stem cell transplant (ASCT). However, many patients with poor prognosis are unable to compete therapy. In ZUMA-7, about 35% of patients in the SOC arm went on the receive on-protocol ASCT. Lack of chemotherapy response was most cited as a reason for not receiving ASCT.
Axi-cel is already approved for use to treat numerous hematologic malignancies, including indications in diffuse large B-cell lymphoma and follicular lymphoma. The treatment carries a boxed warning for cytokine release syndrome and neurologic toxicities, which are common adverse effects associated with this class of therapy.
The recommended dose of axi-cel in 2 × 106 CAR-positive viable T cells/kg, with a maximum of 2 × 108 CAR-positive viable T cells.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.